Biostate AI

Detect disease years early

Houston, TX, US

Biostate AI combines RNA sequencing technology with artificial intelligence for disease diagnosis and drug response prediction. The company has invented and patented novel biomolecular technologies that perform RNA sequencing at a significantly lower cost than traditional approaches, operating as a Laboratory Developed Test (LDT) service provider.

Shareable draft

Check out Biostate AI on @MedStartr Today Biostate AI combines RNA sequencing technology with artificial intelligence for disease diagnosis and drug response prediction. The company has invented and patented novel biomolecular technologies that perform RNA sequencing at a significantly lower cost than traditional approaches, operating as a Laboratory Developed Test (LDT) service provider. #Leukemia #Diabetes #Lymphoma #PostTransplantCare #SkinCancerMelanoma #DrugToxicity #AutoimmuneDiseases #OralCancer #CardiovascularDisease #MultipleSclerosis #CancerOncology #PrecisionMedicineDiagnostics #MedMo #MedStartrVentures

https://www.medstartr.ai/s/Q7vyCV1P7P4

Note, this image was autogenerated by Syggy based on what we know about the company. It is not an official company publication.

Get Involved in Biostate AI

1 engagement

🏢Is this your company? Claim This Profile

Join MedStartr to verify with your work email and edit this profile

How We Help

Problem Statement

Traditional RNA sequencing is expensive and slow, hindering broad accessibility for disease diagnosis and drug response prediction, and research cycles are lengthy.

Core Technology

Proprietary low-cost RNA sequencing technology and AI-driven data analysis platform for disease diagnosis and drug response prediction.

Key Differentiators

Novel biomolecular technologies that perform RNA sequencing at nearly an order of magnitude lower cost than traditional approaches; AI agent that compresses research cycles from years to days (K-Dense Beta)

Clinical Focus

Disease diagnosis; Drug response prediction; Longevity

Company Info

Business Model: Other
Founded: 2024
Total Funding: Only accessible to MedStartr community members. Join now
Only accessible to MedStartr community members.
Join now

Disease Areas

Leukemia Diabetes Lymphoma Post-Transplant Care Skin Cancer & Melanoma Drug Toxicity Autoimmune Disease Oral Cancer Cardiovascular Disease Multiple Sclerosis Cancer & Oncology

Technologies

AI-driven Data AnalysisRNA SequencingAI & Machine Learning

Clinical & IP

🔬

Clinical Validation

K-Dense validated with Harvard Medical School aging research; collaborations with Weill Cornell Medicine (leukemia, MS); 12+ patented technologies; 100+ academic partners

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Biostate AI?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.